Recombinant Vaccinia GM-CSF; RAC VAC GM-CSF (JX-594)

DRUG4 trials

Sponsors

Jennerex Biotherapeutics

Conditions

Carcinoma, ColorectalColorectal CarcinomaEwing's SarcomaLung CancerLymphomaMelanomaNeuroblastomaRenal Cell Carcinoma

Phase 1

Safety Study of Recombinant Vaccinia Virus to Treat Refractory Solid Tumors

CompletedNCT00625456

Jennerex BiotherapeuticsLung Cancer, Melanoma, Renal Cell Carcinoma +1

Start: 2008-06-30End: 2014-06-30Updated: 2015-12-03

Safety Study of Recombinant Vaccinia Virus to Treat Refractory Solid Tumors in Pediatric Patients

CompletedNCT01169584

Jennerex BiotherapeuticsEwing's Sarcoma, Lymphoma, Neuroblastoma +2

Start: 2010-08-31End: 2014-11-30Updated: 2016-01-21

Phase 1b Dose Escalation Study of Intravenous JX-594 in Metastatic, Refractory Colorectal Carcinoma

CompletedNCT01380600

Jennerex BiotherapeuticsCarcinoma, Colorectal

Start: 2010-09-08End: 2012-10-18Updated: 2026-07-08

Phase 2

Neoadjuvant Study of Recombinant Vaccinia Virus to Treat Metastatic Colorectal Carcinoma in Patients Undergoing Complete Resection of Liver Tumors

TerminatedNCT01329809

Jennerex BiotherapeuticsColorectal Carcinoma

Start: 2011-10-31End: 2013-03-31Updated: 2013-04-10